Regeneron works to secure fianlimab
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
ASCO 2023 – in Lag3 Regeneron could beat Bristol Myers Squibb
Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting
